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Summary
Aims/objectives:	In	the	BESIDE	study,	combination	therapy	(antimuscarinic	[solifena-
cin] and β3-	adrenoceptor	 agonist	 [mirabegron])	 improved	 efficacy	 over	 solifenacin	
monotherapy without exacerbating anticholinergic side effects in overactive bladder 
(OAB)	patients;	however,	a	potential	synergistic	effect	on	the	cardiovascular	(CV)	sys-
tem requires investigation.
Methods: OAB	patients	remaining	 incontinent	despite	daily	solifenacin	5	mg	during	
4- week single- blind run- in, were randomised 1:1:1 to double- blind daily combination 
(solifenacin	5	mg/mirabegron	25	mg,	increasing	to	50	mg	after	week	4),	solifenacin	5	
or	 10	mg	 for	 12	weeks.	 CV	 safety	 assessments	 included	 frequency	 of	 CV-	related	
treatment-	emergent	adverse	events	(TEAEs),	change	from	baseline	in	vital	signs	(sys-
tolic	blood	pressure	[SBP],	diastolic	blood	pressure	[DBP],	pulse	rate)	and	electrocar-
diogram	(ECG)	parameters.
Results: The	frequency	of	hypertension,	tachycardia	and	ECG	QT	prolongation,	respec-
tively,	was	low	and	comparable	across	combination	(1.1%,	0.3%,	0.1%),	solifenacin	5	mg	
(0.7%,	0.1%,	0.1%),	and	solifenacin	10	mg	groups	(0.8%,	0%,	0.1%).	Adjusted	mean	(SE)	
change	from	baseline	to	end	of	treatment	(EoT)	in	SBP,	DBP,	and	pulse	rate	with	com-
bination	(0.07	mm	Hg	[0.38],	−0.35	mm	Hg	[0.26],	0.47	bpm	[0.28]),	solifenacin	5	mg	
(−0.93	mm	Hg	 [0.38],	 −0.45	mm	Hg	 [0.26],	 0.43	bpm	 [0.28])	 and	 solifenacin	 10	mg	
(−1.28	mm	Hg	[0.38],	−0.48	mm	Hg	[0.26],	0.27	bpm	[0.28])	was	generally	comparable,	
with	the	exception	of	a	mean	treatment	difference	of	~1	mm	Hg	in	SBP	between	com-
bination	and	solifenacin	monotherapy;	SBP	was	unchanged	with	combination	and	de-
creased	with	 solifenacin	monotherapy.	Mean	 changes	 from	baseline	 to	 EoT	 in	 ECG	
parameters	were	generally	similar	across	treatment	groups,	except	for	QT	interval	cor-
rected	using	Fridericia’s	formula,	which	was	higher	with	solifenacin	10	mg	(3.30	msec-
onds)	vs.	combination	(0.49	mseconds)	and	solifenacin	5	mg	(0.77	mseconds).
Conclusion: The	comparable	 frequency	of	CV-	related	TEAEs,	 changes	 in	vital	 signs	
and	 ECG	 parameters	 indicates	 no	 synergistic	 effect	 on	 CV	 safety	 outcomes	when	 
mirabegron and solifenacin are combined.
This	is	an	open	access	article	under	the	terms	of	the	Creative	Commons	Attribution-NonCommercial	License,	which	permits	use,	distribution	and	reproduction	in	any	
medium, provided the original work is properly cited and is not used for commercial purposes.
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1  | INTRODUCTION
The	symptom	complex	of	overactive	bladder	(OAB)	is	defined	as	uri-
nary urgency, often accompanied by increased daytime micturition 
frequency and nocturia in the absence of urinary tract infection or 
other obvious pathology; urgency incontinence may or may not be 
present.1,2	OAB	is	estimated	to	affect	20%	of	the	global	population	by	
2018.3	Increasing	age	is	the	most	common	risk	factor	for	OAB,	with	
current	prevalence	 rates	of	30%-	40%	 in	patients	aged	≥65	years.4,5 
Males	and	females	are	equally	affected,	however,	certain	symptoms	
predominate	 in	 males	 (urgency	 and	 nocturia)	 and	 females	 (inconti-
nence).6,7	 Since	OAB	 is	 an	 age-	related	 condition,	 significantly	more	
patients	 present	 with	 concomitant	 cardiovascular	 (CV)	 comorbidi-
ties	 (eg,	 hypertension)	 compared	 with	 non-	OAB	 patients,8 which 
emphasises	 the	 importance	 of	 evaluating	 the	 CV	 safety	 of	 OAB	
pharmacotherapies.
The	 two	 available	 oral	 pharmacotherapies—antimuscarinics	
and the β3-	adrenoceptor	 agonist,	 mirabegron—mediate	 relaxation	
of	 the	 bladder	 by	 antagonism	 of	 the	muscarinic	M2	 and	M3 recep-
tor subtypes,9 or stimulation of the β3- adrenoceptor subtype, in the 
urothelium and detrusor muscle.10	Muscarinic	(M2,	M3)	receptors	and	
β-	adrenoceptors	(β1, β2 and β3)	are	also	expressed	in	the	CV	system.	
The	M2 receptor has a functional role in mediating heart rate
11 and 
the	M3 receptor mediates vasodilation,
12 and their antagonism could 
potentially	 increase	blood	pressure	or	heart	rate,	prolong	the	QT	in-
terval	 and	 induce	 polymorphic	 ventricular	 tachycardia	 (torsade	 de	
pointes).11	 The	 β1- adrenoceptor mediates increased heart rate and 
force of contraction and the β2- adrenoceptor mediates vasodilation in 
the vascular smooth muscle.13	The	role	of	the	β3- adrenoceptor is less 
clear in human physiology, however, in vitro, the activation of the β3- 
adrenoceptor induces positive inotropic effects in human atrial tissue 
and negative inotropic effects in ventricular tissue.14	The	antimusca-
rinic,	solifenacin,	is	selective	for	the	M3 subtype,
15 while in-vitro stud-
ies show that mirabegron has a 150- fold and 33- fold higher affinity for 
the β3- vs. β1- and β2- adrenoceptor subtypes.
16	Given	the	location	of	
the	M3 receptor and β3	adrenoceptor	in	CV	tissues,	and	the	high	den-
sity of β1 adrenoceptors in the heart, potential effects on the heart and 
vasculature cannot be excluded when these drugs are used as mono-
therapy or in combination.
Mirabegron	and	solifenacin	share	similar	efficacy	in	the	treatment	
of	OAB,17	and	are	considered	to	have	an	acceptable	CV	safety	pro-
file at therapeutic doses.18,19	As	per	mirabegron’s	 labelling,	 periodic	
blood pressure monitoring is advocated during treatment, and mi-
rabegron is not recommended in patients with severe uncontrolled 
hypertension	 (systolic	blood	pressure	 [SBP]	≥180	mm	Hg	and/or	di-
astolic	blood	pressure	[DBP]	≥110	mm	Hg).20	Given	the	lack	of	anti-
muscarinic	and	mirabegron	data	in	older	patients	with	significant	CV	
risk	factors	in	Phase	III	trials,	it	is	considered	good	clinical	practice	to	
periodically	monitor	 blood	 pressure	 and	 heart	 rate	 in	OAB	patients	
aged >80 years.18,19
OAB	patients	are	usually	initiated	on	an	antimuscarinic,	however,	
persistence is often poor because of bothersome anticholinergic side 
effects	(eg,	blurred	vision,	dry	mouth)	or	inadequate	improvement	in	
symptoms.21,22	Switching	to	an	alternative	antimuscarinic	usually	has	
little impact in terms of improved persistence,23 while dose escalation 
can often exacerbate the anticholinergic burden leading to treatment 
discontinuation.21,24
Several	 OAB	 trials	 investigating	 combinations	 of	 solifenacin	
(2.5/5/10	mg)	and	mirabegron	(25/50	mg)	have	demonstrated	an	ad-
ditive benefit in efficacy without compromising safety vs. solifenacin 
monotherapy.25–27	In	the	BESIDE	study	(NCT01908829),	adding	mira-
begron	50	mg	to	solifenacin	5	mg	further	improved	OAB	symptoms	and	
patient- reported outcomes vs. solifenacin 5 mg or 10 mg, and was well- 
tolerated	in	OAB	patients	remaining	incontinent	after	initial	solifenacin	
5 mg.25,28	Herein,	we	report	on	the	CV	safety	outcomes	from	BESIDE	
including subpopulations stratified by hypertensive status and gender 
(age-	related	CV	safety	will	be	reported	in	a	subsequent	manuscript).
2  | METHODS
2.1 | Study design and participants
The	methodology	for	BESIDE	has	been	previously	described.25 In sum-
mary,	 adults	with	OAB	 symptoms	 for	≥3	months	 entered	 a	2-	week	
screening/wash- out period, followed by a run- in period with single- 
blind daily solifenacin 5 mg for 4 weeks provided they reported an 
average	of	≥2	incontinence	episodes/24	h	prior	to	the	run-	in	period.	
Patients	remaining	incontinent	at	baseline	(≥1	episode	during	the	3-	
day	bladder	diary),	who	satisfied	inclusion,	and	did	not	meet	exclusion	
criteria, were randomised 1:1:1- 12 weeks of daily double- blind treat-
ment	with	combination	(solifenacin	5	mg/mirabegron	25	mg,	increas-
ing	to	50	mg	after	week	4),	solifenacin	5	mg	or	10	mg	monotherapy.
What’s known
•	 A	 combination	 of	 antimuscarinic	 (solifenacin	 5	mg)	 and	
β3-adrenoceptor	 agonist	 (mirabegron	 50	mg)	 improves	
efficacy without exacerbating anticholinergic side effects 
vs.	 solifenacin	monotherapy	 (5	mg,	 10	mg)	 in	 the	 treat-
ment	of	overactive	bladder	(OAB).
•	 Cardiovascular	 (CV)	comorbidities	are	more	prevalent	 in	
OAB	patients	compared	with	the	non-OAB	population.
•	 Mirabegron	 and	 solifenacin	 in	 combination	may	 poten-
tially	affect	the	CV	system;	however,	monotherapy	use	at	
therapeutic	doses	indicates	no	CV	safety	concerns.
What’s new
• Using a combination of mirabegron and solifenacin does 
not	have	a	synergistic	effect	on	the	CV	system	since	the	
frequency	 of	 CV-related	 treatment-emergent	 adverse	
events,	 change	 in	 vital	 signs	 and	 ECG	 parameters	 are	
comparable	 with	 solifenacin	 monotherapy	 (5	mg	 and	
10	mg).
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2.2 | CV safety assessment
The	 frequency	 of	 CV-	related	 treatment-	emergent	 adverse	 events	
(TEAEs)	 was	 assessed	 during	 the	 study	 and	 2-	week	 follow-	up	 and	
included	increased	blood	pressure,	QT	prolongation,	increased	heart	
rate,	 tachycardia,	 atrial	 fibrillation,	 and	 palpitations.	 Potentially	 se-
rious	 CV-	related	 events	 were	 adjudicated	 by	 the	 Independent	
Cardiovascular	 Adjudication	 Committee	 and	 were	 summarised	 by	
type	of	CV	event	 (Antiplatelet	Trialists’	Collaboration	 [APTC]/Major	
Adverse	 Cardiovascular	 Events	 [MACE]	 or	 non-	APTC/MACE)	 and	
non-	CV	event.
For	vital	signs	(SBP,	DBP,	and	pulse	rate),	triplicate	readings	were	
measured	on	 site	 at	 screening,	 randomisation	 (baseline),	 and	each	
follow- up visit and the average of the last two readings was used 
to	derive	the	average	per	analysis	visit.	The	change	from	baseline	to	
end	of	treatment	(EoT)	in	vital	signs	in	the	overall	population,	and	ac-
cording to subpopulations based on hypertension status at screen-
ing and β- blocker use during the treatment period were previously 
presented	 in	 the	 primary	 analysis	 of	 BESIDE,25 and the adjusted 
change	from	baseline	to	EoT	values	are	summarised	in	this	analysis.	
Additional	 sensitivity	 analyses	 included	 a	 factor	 for	 antihyperten-
sive	use	at	 screening	or	a	different	age	group	 factor	 (<45,	≥45	 to	
<65,	≥65	years)	in	the	model.	Change	in	vital	signs	was	also	strati-
fied	by	gender.	Shift	in	vital	sign	severity	according	to	four	catego-
ries	 of	 average	 blood	pressure	 readings	 ([i]	 SBP	<140	mm	Hg	 and	
DBP	<90	mm	Hg;	[ii]	SBP	≥140-	159	mm	Hg	or	DBP	≥90-	99	mm	Hg;	
[iii]	 SBP	 ≥160-	179	mm	Hg	 or	 DBP	 ≥100-	109	mm	Hg;	 [iv]	 SBP	
≥180	mm	Hg	 or	 DBP	 ≥110	mm	Hg)	was	 assessed	 in	 terms	 of	 the	
percentage of patients who experienced “no shift”, “categorical in-
crease”,	or	“categorical	decrease”	from	baseline	to	EoT.	The	percent-
age	of	patients	meeting	change	from	baseline	criteria	for	SBP	(≥10,	
15,	 20	mm	Hg),	 DBP	 (≥5,	 10,	 15	mm	Hg),	 and	 pulse	 rate	 (≥5,	 10,	
15	bpm)	at	 three	consecutive	postbaseline	visits	was	presented	 in	
the overall population and in the subpopulations based on hyperten-
sive status at screening or β-	blocker	use.	The	percentage	of	patients	
in the overall population who experienced potentially clinically sig-
nificant	changes	in	vital	signs	(SBP	[≥180	mm	Hg	and	a	≥20	mm	Hg	
change	from	baseline];	DBP	[≥105	mm	Hg	and	≥15	mm	Hg	change	
from	 baseline];	 pulse	 rate	 [≥120	bpm	 and	 ≥15	bpm	 change	 from	
baseline])	was	also	reported.
Twelve-	lead	 electrocardiograms	 (ECGs)	 were	 performed	 at	
screening,	baseline	(week	0)	and	at	each	follow-	up	visit	with	the	pa-
tient in the supine position, after the patient had been lying down 
for	 15	minutes.	 Triplicate	 ECGs	were	 recorded	with	 an	 interval	 of	
at	least	5	minutes	between	each	ECG,	made	at	a	speed	of	25	mm/s	
and all leads including at least 4 complexes. Interpretation of the 
ECG	was	undertaken	by	the	investigator	(not	reported	in	this	anal-
ysis)	 and	by	an	 independent	central	 reader.	The	percentage	of	pa-
tients with abnormal/normal readings were reported at each visit. 
The	mean	values	and	change	from	baseline	at	EoT	 in	the	PR	 inter-
val,	RR	 interval,	QRS	 interval,	QT	 interval	 corrected	by	Fridericia’s	
formula	 (QTcF),	 and	 heart	 rate	 are	 reported	 in	 the	 overall	 popu-
lation.	 The	 frequency	 of	 QTcF	 extreme	 values	 (>450	mseconds,	
>480	mseconds	and	>500	mseconds)	and	extremes	in	change	from	
baseline	 (>30	mseconds	 and	 >60	mseconds)	were	 reported	 during	
double- blind treatment in the overall population and stratified by 
gender.	For	the	interpretation	of	the	ECGs	by	the	central	reader,	the	
percentage of patients who had “no categorical change”, “abnormal 
to normal” and “normal to abnormal” during double- blind treatment 
were presented.
2.3 | Statistical analysis
Sample	size	calculations	related	to	categorical	changes	in	the	primary	
efficacy	endpoint	(incontinence	episodes/24	h),	were	based	on	previ-
ous studies with mirabegron alone and in combination with solifena-
cin,	and	are	described	in	the	primary	analysis	of	BESIDE.25	The	safety	
analysis	set	(SAF)	consisted	of	all	randomised	patients	who	received	
≥1	dose	of	double-	blind	treatment	and	was	used	for	the	analysis	of	
CV	safety	variables.
CV	TEAEs	of	 interest	 (increased	blood	pressure;	QT	prolonga-
tion; increased heart rate, tachycardia, atrial fibrillation and palpi-
tations)	were	identified	using	standardised	MedRA	queries	(v16.0).	
The	percentage	of	patients	who	reported	≥1	AE	were	summarised	
by	System	Organ	Class	and	Preferred	Term	by	treatment	with	corre-
sponding	95%	CI.	Tachycardia	was	reported	as	a	TEAE	according	to	
the	investigator’s	judgement	independent	of	a	pulse	rate	≥100	bpm.	
Tachycardia	was	also	reported	according	to	the	standardised	assess-
ment	of	vital	sign	data	based	on	a	mean	pulse	rate	≥100	bpm.
The	 average	 change	 from	 baseline	 to	 EoT	 for	 vital	 signs	 was	
analysed	 using	 an	 analysis	 of	 covariance	 (ANCOVA)	model	which	
included	treatment	group,	randomisation	stratification	factors	(gen-
der,	 age	group	<65	and	≥65	years,	 geographic	 region	 and	4-	week	
incontinence	episode	reduction	group)	as	fixed	factors	and	baseline	
vital sign value as a covariate. Least squares mean estimates and 
two-	sided	95%	CIs	for	the	mean	changes	from	baseline	within	each	
treatment group, as well as for the difference in change from base-
line between combination therapy vs. solifenacin 5 mg and 10 mg, 
were	 derived	with	 two-	sided	 95%	 CIs.	 The	 study	was	 only	 pow-
ered for efficacy endpoints, thus no P- values were calculated for 
vital	 sign	differences.	 Populations	 for	vital	 sign	 analyses	 included:	
(i)	overall	 (any	patient	 in	the	SAF);	 (ii)	past	history	of	hypertension	
(medical	 history	 of	 hypertension	 and	no	 concurrent	 antihyperten-
sive	treatment	at	screening);	(iii)	hypertensive	at	screening	(medical	
history of hypertension and concurrent antihypertensive treatment 
at	screening);	(iv)	no	hypertension	at	screening;	(v)	use	of	β- blockers 
(≥1	dose	during	the	run-	in	period	and	≥1	dose	during	double-	blind	
treatment);	 (vi)	 no	use	of	β- blockers. For patients meeting change 
from baseline criteria in vital signs, percentages are based on the 
total number in each treatment group with non- missing values. 
Additional	sensitivity	analyses	were	performed	including	antihyper-
tensive	use	at	screening	or	a	different	age	group	factor	 (<45,	≥45	
to	<65,	≥65	years)	in	the	ANCOVA	model	to	analyse	changes	from	
baseline in vital signs.
Heart	rate,	PR	 interval,	RR	 interval,	QRS	 interval	and	QTcF	were	
summarised descriptively for each treatment group at each visit 
4 of 15  |     DRAKE Et Al.
including	changes	from	baseline	to	each	postbaseline	visit.	The	worst	
non-	missing	value	was	used	in	the	analysis	for	categorical	ECG	vari-
ables reported by the central reader.
3  | RESULTS
3.1 | Patient demographics and baseline 
characteristics
Overall, 2174 patients were randomised into the study, of which 
2172	 (99.9%)	 received	 double-	blind	 study	 drug	 and	 were	 in-
cluded	 in	 the	 safety	 analysis	 set	 (SAF).	 The	 discontinuation	 rate	
(post-randomisation)	was	 low	 (6.2%)	with	no	 relevant	differences	
among	 treatment	 groups.	The	overall	mean	 age	 at	 screening	was	
57.5	years.	Approximately	37%	of	patients	had	a	history	of	hyper-
tension	and	approximately	7.5%	and	4.5%,	 respectively,	had	 type	
1 and type 2 diabetes mellitus in each treatment group at base-
line	 (Table	1).	The	most	 frequently	 reported	concomitant	medica-
tions during treatment were agents acting on the renin- angiotensin 
system	 (~27%);	medication	use	was	comparable	across	 treatment	
groups	(Table	1).
3.2 | CV- related TEAEs
Overall,	 the	 frequency	of	TEAEs	of	 interest	 related	 to	 the	CV	 sys-
tem	(increased	blood	pressure;	QT	prolongation;	increased	heart	rate,	
tachycardia,	 atrial	 fibrillation	and	palpitations)	was	 low	 (<2.0%)	and	
comparable	 across	 treatment	 groups.	Hypertension	 as	 a	 TEAE	was	
reported	 in	19	patients	 (combination	n=8,	 [1.1%],	 solifenacin	5	mg,	
n=5	 [0.7%],	 solifenacin	 10	mg,	 n=6	 [0.8%])	 (Table	2).	 One	 patient	
(0.1%)	 in	 each	group	had	ECG	QT	prolongation	 (the	 three	patients	
were	female	with	QTcF	readings	that	ranged	from	447	mseconds	to	
476	mseconds).	Tachycardia	was	reported	as	a	TEAE	in	three	patients	
(combination,	 n=2	 [0.3%];	 solifenacin	 5	mg,	 n=1	 [0.1%]);	 ECG	 and	
vital sign results confirmed heart rate was no more than 102 bpm in 
these	patients.	Seven	serious	CV-	related	TEAEs	were	reported:	acute	
myocardial	infarction	(n=1	[0.1%],	solifenacin	10	mg),	atrial	fibrillation	
(n=1	 [0.1%],	 solifenacin	5	mg),	 atrioventricular	block	complete	 (n=1	
[0.1%],	combination)	arteriogram	coronary	normal	(n=1	[0.1%],	com-
bination),	transient	ischaemic	attack	(n=1	[0.1%],	solifenacin	10	mg),	
hypertensive	 crisis	 (n=1	 [0.1%],	 solifenacin	 10	mg)	 and	 thrombosis	
(n=1,	 solifenacin	 5	mg).	 The	 patient	 in	 the	 solifenacin	 10	mg	 group	
who experienced hypertensive crisis required hospitalisation for 
1	day	and	temporary	cessation	of	solifenacin	treatment.	The	patient	
experiencing atrioventricular block in the combination group had a 
cardiac	 history	 (ie,	 previous	 cardiac	 surgery,	 myocardial	 infarction,	
and	aortic	aneurysm)	and	second	degree	block	prior	to	double-	blind	
treatment.	The	case	of	thrombosis	developed	in	a	previous	femoral	
bypass.	 The	 coronary	 arteriogram	 was	 requested	 after	 an	 episode	
of pneumonia that was considered clinically significant by the study 
investigator.	None	of	 the	seven	serious	TEAEs	were	considered	by	
the	 investigator	 to	be	 related	 to	 treatment.	 Ten	potentially	 serious	
CV-	related	TEAEs	were	reviewed	by	the	adjudication	committee.	This	
included	five	non-	APTC/MACE	CV	events	(combination	n=1	[0.1%],	
solifenacin	5	mg	n=2	 [0.3%]	and	solifenacin	10	mg	n=2	 [0.3%])	and	
one	APTC/MACE	CV	event	 (non-	fatal	myocardial	 infarction)	 in	 the	
solifenacin 10 mg group. In addition, there was one event in the solif-
enacin 10 mg group for which there was insufficient data to adjudi-
cate, and three events in the combination group were adjudicated as 
non-	CV	events.
3.3 | Vital signs
In	 the	overall	 SAF	population,	 the	 adjusted	mean	 (SE)	 change	 from	
baseline	to	EoT	in	SBP	was	0.07	(0.38),	−0.93	(0.38)	and	−1.28	(0.38)	
for combination, solifenacin 5 mg and solifenacin 10 mg groups, re-
spectively; resulting in a mean difference of ~1 mm Hg in the combi-
nation	group	vs.	solifenacin	monotherapy.	There	were	no	appreciable	
differences between combination and solifenacin monotherapy for 
DBP	and	pulse	rate:	the	adjusted	mean	(SE)	change	from	baseline	to	
EoT	 in	DBP	was	−0.35	 (0.26),	 −0.45	 (0.26)	 and	−0.48	 (0.26)	 and	 in	
pulse	rate	was	0.47	(0.28),	0.43	(0.28)	and	0.27	(0.28)	in	the	combi-
nation, solifenacin 5 mg and solifenacin 10 mg groups, respectively. 
There	were	no	notable	 differences	 between	 combination	 and	 solif-
enacin monotherapies in vital signs in subpopulations stratified by hy-
pertensive status and β- blocker use, in the sensitivity analyses using a 
different age group factor or hypertensive medication use at screen-
ing	 in	 the	model	 (Figure	1),	 and	 between	male	 and	 female	 patients	
(Table	3).
The	 percentage	 of	 patients	 with	 increases	 in	 vital	 signs	 at	 EoT	
that met the change from baseline criteria at three consecutive visits 
was low and similar across treatment groups in the overall population 
(Figure	2A-	C).	Similar	findings	were	evident	in	the	subpopulations	ac-
cording to hypertension history, hypertensive status at screening and 
β- blocker use, with the exception of pulse rate in the past history of 
hypertension	cohort	(n=53)	in	which	no	more	than	3/17	(17.6%)	pa-
tients receiving combination met one of the three criteria for change 
from	baseline	vs.	none	in	the	solifenacin	groups	(Table	4).
At	EoT,	a	similar	proportion	of	patients	(~80%)	in	each	treatment	
group	had	no	shift	in	vital	sign	severity,	while	less	than	10%	of	patients	
in	each	group	experienced	a	categorical	increase	(Figure	3);	three	pa-
tients	(n=1	combination,	n=1	solifenacin	5	mg,	n=1	solifenacin	10	mg)	
shifted	to	severity	category	4	(SBP	≥180	mm	Hg	and	DBP=100	mm	Hg)	
from	category	2	(SBP	≥140-	159	mm	Hg	and	DBP	≥90-	99	mm	Hg).
During the treatment period, potentially clinically significant 
values	in	DBP	(≥105	mm	Hg	and	≥15	mm	Hg	change	from	baseline)	
were	observed	in	six	patients	(n=2	[solifenacin	5	mg	at	week	4],	n=3	
[solifenacin	10	mg	during	the	study],	and	n=1	[combination	at	week	
12]),	and	 in	SBP	 (≥180	mm	Hg	and	≥20	mm	Hg	change	 from	base-
line)	 in	 two	patients	 (solifenacin	10	mg	group	at	week	4	 [n=1]	and	
8	[n=1]).
The	 frequency	 of	 tachycardia,	 according	 to	 the	 standardised	
assessment of vital sign data, and defined as an average pulse rate 
≥100	bpm,	was	 low	 and	 similar	 across	 groups	 during	 the	 treatment	
period	 (combination	 n=8,	 1.1%;	 solifenacin	 5	mg	 n=12,	 1.7%	 and	 
solifenacin	10	mg	n=10,	1.4%).
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TABLE  1 Patient	demographics	and	CV-	related	baseline	characteristics	(SAF)
Combination  
n=725
Solifenacin 5 mg  
n=728
Solifenacin 10 mg 
n=719
Sex,	n	(%)
Female 603	(83.2) 604	(83.0) 600	(83.4)
Male 122	(16.8) 124	(17.0) 119	(16.6)
Race,	n	(%)
White 688	(94.9) 679	(93.3) 680	(94.6)
Black/African	American 20	(2.8) 24	(3.3) 27	(3.8)
Asian 13	(1.8) 21	(2.9) 10	(1.4)
Other 4	(0.6) 4	(0.5) 2	(0.3)
Mean	(SD)	age,	year 58.2	(13.1) 56.9	(13.5) 57.3	(13.3)
≥65	year,	n	(%) 231	(31.9) 226	(31.0) 224	(31.2)
≥75	year,	n	(%) 73	(10.1) 66	(9.1) 55	(7.6)
BMI	(kg/m2)
Mean	(SD) 28.9	(5.9) 29.1	(6.2) 28.9	(6.0)
Previous	OAB	medication	(prior	to	screening),	n	(%) 485	(66.9) 503	(69.1) 491	(68.3)
CV	history	(system	organ	class,	preferred	term)	affecting	≥1%	of	patients	in	any	treatment	group,	n	(%)
Vascular	disorders 308	(42.5) 294	(40.4) 283	(39.4)
Hypertension 270	(37.2) 262	(36.0) 262	(36.4)
Varicose	vein 35	(4.8) 21	(2.9) 19	(2.6)
Essential hypertension 2	(0.3) 10	(1.4) 3	(0.4)
Venous	insufficiency 4	(0.6) 7	(1.0) 4	(0.6)
Cardiac disorders 62	(8.6) 59	(8.1) 61	(8.5)
Myocardial	ischaemia 14	(1.9) 12	(1.6) 14	(1.9)
Coronary artery disease 14	(1.9) 15	(2.1) 6	(0.8)
Myocardial	infarction 7	(1.0) 5	(0.7) 9	(1.3)
Arrhythmia 7	(1.0) 2	(0.3) 5	(0.7)
Metabolism	and	nutrition	disorders 191	(26.3) 211	(29.0) 199	(27.7)
Hypercholesterolaemia 67	(9.2) 95	(13.0) 74	(10.3)
Diabetes mellitus 45	(6.2) 66	(9.1) 51	(7.1)
Obesity 43	(5.9) 37	(5.1) 37	(5.1)
Type	2	diabetes	mellitus 23	(3.2) 43	(5.9) 30	(4.2)
Hyperlipidaemia 23	(3.2) 26	(3.6) 35	(4.9)
Dyslipidaemia 12	(1.7) 9	(1.2) 13	(1.8)
Vitamin	D	deficiency 8	(1.1) 6	(0.8) 10	(1.4)
Gout 8	(1.1) 5	(0.7) 5	(0.7)
Hyperuricaemia 2	(0.3) 7	(1.0) 5	(0.7)
CV-	related	concomitant	medication	use	during	double	blind	treatment	period,	n	(%)
Antihypertensivesa 22	(3.0) 17	(2.3) 9	(1.3)
β- blocking agents 90	(12.4) 95	(13.0) 101	(14.0)
Calcium channel blockers 53	(7.3) 49	(6.7) 48	(6.7)
Agents	acting	on	renin-	angiotensin	system 205	(28.3) 196	(26.9) 194	(27.0)
Lipid- modifying agents 119	(16.4) 152	(20.9) 130	(18.1)
Antithrombotic	agents 97	(13.4) 95	(13.0) 81	(11.3)
Drugs used in diabetes 62	(8.6) 95	(13.0) 75	(10.4)
Cardiac therapy 57	(7.9) 74	(10.2) 51	(7.1)
(Continues)
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3.4 | ECG results
Mean	 changes	 from	 baseline	 to	 EoT	 in	 ECG	 parameters	 (PR,	 RR,	
QRS,	QTcF	and	heart	rate)	were	generally	similar	across	treatment	
groups;	 the	 most	 notable	 exception	 being	 the	 QTcF,	 which	 was	
higher	in	the	solifenacin	10	mg	(3.30	mseconds)	group	vs.	combina-
tion	(0.49	mseconds)	and	solifenacin	5	mg	(0.77	mseconds)	(Table	5).	
The	percentage	of	patients	with	a	normal	 (~72%-	75%)	and	abnor-
mal	(~25%-	28%)	ECG	assessment	at	baseline	and	at	each	visit	was	
comparable	across	each	treatment	group.	This	was	reflected	by	the	
observation	that	>80%	of	patients	 in	each	group	had	no	change	in	
ECG	interpretation	(Figure	4).	During	double-	blind	treatment,	there	
were	no	patients	with	a	mean	QTcF	value	>500	mseconds,	and	11	
patients	had	mean	QTcF	values	>480	mseconds	 (combination	n=4	
[0.6%]	and	solifenacin	10	mg	n=7	[1.0%]).	A	slightly	higher	propor-
tion of patients in the solifenacin 10 mg group had mean changes 
from	 baseline	 of	 >30	mseconds	 and	 >60	mseconds	 in	 QTcF	 com-
pared	 with	 combination	 and	 solifenacin	 5	mg	 (Figure	5A).	 There	
were	 no	 notable	 treatment	 differences	 in	 QTcF	 values	 or	 change	
from baseline by gender; however, in general, females were more 
likely	 to	 experience	 a	 QTcF	 >450	mseconds	 and	 >480	mseconds,	
and	 a	 change	 from	 baseline	 >60	mseconds	 compared	 with	 males	
(Figure	5B	and	C).
4  | DISCUSSION
CV	safety	concerns	are	particularly	relevant	in	chronic	medical	con-
ditions	such	as	OAB,	 in	which	patients	have	a	 significantly	higher	
rate	of	pre-	existing	CV	comorbidities	than	patients	without	OAB.8 
Of	 the	 two	 oral	 pharmacotherapies	 investigated	 in	BESIDE,	 solif-
enacin	 selectively	 inhibits	 the	 M3 receptor subtype in the para-
sympathetic system, and mirabegron selectively stimulates the β3 
adrenoceptor in the sympathetic system, hence the potential for 
additional systemic effects beyond the bladder, including the heart 
and	 vasculature.	 OAB	 studies	 investigating	 mirabegron	 mono-
therapy	 (25	mg/d	 or	 50	mg/d)	 for	 12	weeks	 and	 12	months,	 or	
solifenacin	 (5	mg/d	 or	 10	mg/d)	monotherapy	 for	 12	weeks	 have	
not	 demonstrated	 an	 increased	 CV	 risk,	 with	 no	 clinically	 rele-
vant changes in cardiac function or blood pressure reported.18,19 
However, the concomitant exposure to these agents with distinct 
mechanisms of action raises the potential for a synergistic effect on 
the	CV	system.
This	assessment	from	the	BESIDE	study	is	the	first	to	investigate	
CV	safety	in	OAB	patients	treated	with	a	combination	of	mirabegron	
and	solifenacin.	The	OAB	population	represents	a	real-	life	clinical	set-
ting characterised by refractory, treatment- experienced patients with 
a	moderate	level	of	CV	risk	(ie,	hypertension,	diabetes)	and	polyphar-
macy; almost one- third of the population were controlled hyperten-
sive	patients.	In	this	analysis	of	CV	safety,	the	frequency	of	CV	TEAEs,	
and	change	in	vital	signs	and	ECG	results,	were	comparable	between	
combination	 therapy	 and	 solifenacin	 monotherapy	 (5	mg	 or	 10	mg)	
confirming	no	synergistic	effect	on	the	CV	system	regardless	of	pre-	
existing	CV	 risk	 factors	 (eg,	hypertension	history	or	hypertensive	at	
screening).
The	frequency	of	CV	TEAEs	and	the	magnitude	of	change	in	vital	
signs	and	ECG	parameters	with	combination	therapy	is	consistent	with	
mirabegron and solifenacin monotherapy,18,19 and with other studies 
that have investigated a combination of mirabegron and solifena-
cin	 in	 a	 Japanese	OAB	population26	 and	 in	 a	 Phase	 II	 dose-	ranging	
study.27	The	frequency	of	hypertension	(<2%)	across	treatment	groups	
in	BESIDE	is	considerably	lower	than	that	reported	with	placebo	and	
mirabegron	monotherapy	in	previous	12-	week	Phase	III	studies	(pla-
cebo	n=7.6%,	mirabegron	50	mg	n=7.5%).29 However, hypertension 
was	 defined	 using	 three	 prespecified	 criteria	 in	 the	 previous	 Phase	
III	monotherapy	trials,	whereas	 in	BESIDE	there	were	no	predefined	
criteria	and	hypertension	was	 reported	as	an	AE,	 if	 considered	clin-
ically	 relevant	by	 the	 investigator.	Similarly,	 the	overall	 frequency	of	
Combination  
n=725
Solifenacin 5 mg  
n=728
Solifenacin 10 mg 
n=719
Vital	signs,	mean	(SD) n=724 n=728 n=719
SBP	mm	Hg 126.73	(13.83) 125.63	(14.24) 125.88	(14.64)
DBP	mm	Hg 76.43	(8.31) 76.15	(8.63) 75.70	(8.41)
Pulse	rate	bpm 71.35	(9.62) 71.33	(9.47) 71.17	(9.20)	
[n=718]
ECG	parameters	(Central	reader)	n	(%) n=721 n=727 n=719
QTcF	>450	mseconds 31	(4.3) 24	(3.3) 17	(2.4)
QTcF	>480	mseconds 1	(0.1) 1	(0.1) 0
QTcF	>500	mseconds 0 0 0
BMI,	body	mass	index;	CV,	cardiovascular;	DBP,	diastolic	blood	pressure;	ECG,	electrocardiogram;	OAB,	overactive	bladder;	QTcF,	QT	interval	corrected	
using	Fridericia’s	formula;	SBP,	systolic	blood	pressure;	SE,	standard	error.
aAlpha	adrenoceptor	antagonists,	imidazoline	receptor	agonists,	tadalafil,	magnesium	sulphate,	pyrimidine	derivatives,	hydrazinophthalazine	derivatives,	
methyldopa, rauwolfia alkaloids.
TABLE  1  (Continued)
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TABLE  2 Treatment-	emergent	adverse	events	(TEAEs)	(MedRA	v16.0)	of	interest	related	to	the	CV	system,	serious	CV-	related	TEAEs	and	
frequency	of	adjudicated	CV-	related	TEAEs	(SAF)
TEAEs of interest SOC and PT
Patients, n (%) [95% CI]
Combination  
(n=725)
Solifenacin 5 mg  
(n=728)
Solifenacin 10 mg 
(n=719)
Increased blood pressure
Overall 12	(1.7)	[0.7	to		2.6] 6	(0.8)	[0.2	to		1.5] 13	(1.8)	[0.8	to		2.8]
Vascular	disorders 8	(1.1)	[0.3	to		1.9] 5	(0.7)	[0.1	to		1.3] 7	(1.0)	[0.3	to		1.7]
Hypertension 8	(1.1)	[0.3	to		1.9] 5	(0.7)	[0.1	to		1.3] 6	(0.8)	[0.2	to		1.5]
Hypertensive crisis 0 0 1	(0.1)	[0.0	to		0.4]
Investigations 4	(0.6)	[0.0	to		1.1] 1	(0.1)	[0.0	to		0.4] 6	(0.8)	[0.2	to		1.5]
Blood pressure increased 4	(0.6)	[0.0	to		1.1] 1	(0.1)	[0.0	to		0.4] 6	(0.8)	[0.2	to		1.5]
QT	prolongation
Overall 1	(0.1)	[0.0	to		0.4] 1	(0.1)	[0.0	to		0.4] 2	(0.3)	[0.0	to		0.7]
Investigations 1	(0.1)	[0.0	to		0.4] 1	(0.1)	[0.0	to		0.4] 1	(0.1)	[0.0	to		0.4]
ECG	QT	prolonged 1	(0.1)	[0.0	to		0.4] 1	(0.1)	[0.0	to		0.4] 1	(0.1)	[0.0	to		0.4]
Nervous system disorders 0 0 1	(0.1)	[0.0	to		0.4]
Syncope 0 0 1	(0.1)	[0.0	to		0.4]
Increased heart rate, tachycardia, atrial fibrillation and palpitations
Overall 7	(1.0)	[0.3	to		1.7] 5	(0.7)	[0.1	to		1.3] 4	(0.6)	[0.0	to		1.1]
Cardiac disorders 7a	(1.0)	[0.3	to		1.7] 5	(0.7)	[0.1	to		1.3] 3	(0.4)	[0.0	to		0.9]
Palpitations 6	(0.8)	[0.2	to		1.5] 2	(0.3)	[0.0	to		0.7] 2	(0.3)	[0.0	to		0.7]
Tachycardia 2	(0.3)	[0.0	to		0.7] 1	(0.1)	[0.0	to		0.4] 0
Atrial	fibrillation 0 1	(0.1)	[0.0	to		0.4] 0
Supraventricular	extrasystoles 0 0 1	(0.1)	[0.0	to		0.4]
Ventricular	extrasystoles 0 1	(0.1)	[0.0	to		0.4] 0
Nervous system disorders 0 0 1	(0.1)	[0.0	to		0.4]
Syncope 0 0 1	(0.1)	[0.0	to		0.4]
Serious	CV-related	TEAEs	(PT	only)
Arteriogram	coronary	normal 1	(0.1) 0 0
Acute	myocardial	infarction 0 0 1	(0.1)
Atrial	fibrillation 0 1	(0.1) 0
Atrioventricular	block	complete 1	(0.1) 0 0
Transient	ischaemic	attack 0 0 1	(0.1)
Hypertensive crisis 0 0 1	(0.1)
Thrombosis 0 1	(0.1) 0
Adjudicated	serious	CV-	related	TEAEs
Overall 4	(0.6) 2	(0.3) 4	(0.6)
APTC/MACE	CV	events 0 0 1	(0.1)
Non- fatal myocardial infarction 0 0 1	(0.1)
Non- fatal stroke 0 0 0
CV	death 0 0 0
Non-	APTC/MACE	CV	events 1	(0.1) 2	(0.3) 2	(0.3)
Unstable angina 0 0 0
Coronary revascularization 0 0 0
Transient	ischaemic	attack 0 0 1	(0.1)
Venous	and	peripheral	arterial	vascular	thrombotic	
event
0 1	(0.1) 0
(Continues)
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TEAEs of interest SOC and PT
Patients, n (%) [95% CI]
Combination  
(n=725)
Solifenacin 5 mg  
(n=728)
Solifenacin 10 mg 
(n=719)
Congestive heart failure 0 0 0
Arrhythmia,	no	evidence	of	ischaemia 1	(0.1) 1	(0.1) 0
Other	serious	non-	MACE	CV	event 0 0 1	(0.1)
Other 3	(0.4) 0 1	(0.1)
Insufficient data 0 0 1	(0.1)
Non-	CV	event 3	(0.4) 0 0
APTC,	antiplatelet	trialists	collaboration;	CV,	cardiovascular;	ECG,	electrocardiogram;	MACE,	major	adverse	cardiovascular	event;	PT,	preferred	term;	SOC,	
system	organ	class;	TEAEs,	treatment-	emergent	adverse	events.
TEAE	refers	to	an	AE	which	started	or	worsened	in	the	period	from	first	double-	blind	medication	intake	until	30	days	after	the	last	double-	blind	medication	intake.
aOne patient experienced both tachycardia and palpitations; the patient is counted once under each of palpitations and tachycardia, but only once under 
the	SOC	cardiac	disorders.
TABLE  2  (Continued)
F IGURE  1 Adjusted	change	from	baseline	to	EoT	for	vital	signs	in	the	overall	population	and	by	sensitivity	analyses:	A,	systolic	blood	
pressure:	combination	vs.	solifenacin	5	mg	and	10	mg;	B,	diastolic	blood	pressure:	combination	vs.	solifenacin	5	mg	and	10	mg;	C,	Pulse	rate:	
combination vs. solifenacin 5 mg and 10 mg
Systolic blood pressure (mm Hg): combination vs solifenacin 5 mg
1.01 (95% CI: –0.06, 2.07)
–0.67 (95% CI: –7.89, 6.55)
1.74 (95% CI: –0.27, 3.75)
0.64 (95% CI: –0.58, 1.85)
1.68 (95% CI: –1.94, 5.30)
0.85 (95% CI: –0.26, 1.95)
0.88 (95% CI: –0.18, 1.94)
1.05 (95% CI: –0.01, 2.11)
Systolic blood pressure (mm Hg): combination vs solifenacin 10 mg
1.35 (95% CI: 0.29, 2.42)
0.99 (95% CI: –6.26, 8.24)
2.42 (95% CI: 0.40, 4.44)
0.70 (95% CI: –0.51, 1.91)
1.58 (95% CI: –1.96, 5.11)
1.27 (95% CI: 0.16, 2.38)
1.30 (95% CI: 0.24, 2.36)
1.36 (95% CI: 0.30, 2.42)
Overall safety analysis set
Patients with past history of hypertension
Patients hypertensive at screening
Patients with no hypertension at screening
β-blocker users
Non β-blocker users
With age group (<45, ≥45 to <65, ≥65 years)
With antihypertensive use at screening
Overall safety analysis set
Patients with past history of hypertension
Patients hypertensive at screening
Patients with no hypertension at screening
β-blocker users
Non β-blocker users
With age group (<45, ≥45 to <65, ≥65 years)
With antihypertensive use at screening
Adjusted change from baseline to EoT Adjusted change from baseline to  EoT
–10–10 –5–5 00 5 5 1010
Diastolic blood pressure (mm Hg): combination vs solifenacin 5 mg
0.10 (95% CI: –0.61, 0.82)
1.05 (95% CI: –4.20, 6.30)
0.27 (95% CI: –0.99, 1.52)
0 (95% CI: –0.87, 0.87)
0.85 (95% CI: –1.34, 3.03)
–0.04 (95% CI: –0.80, 0.72)
0.05 (95% CI: –0.67, 0.76)
0.11 (95% CI: –0.60, 0.83)
Diastolic blood pressure (mm Hg): combination vs solifenacin 10 mg
0.13 (95% CI: –0.59, 0.85)
–1.25 (95% CI: –6.60, 4.11)
0.67 (95% CI: –0.59, 1.94)
–0.13 (95% CI: –1.0, 0.74)
0.23 (95% CI: –1.89, 2.36)
0.09 (95% CI: –0.67, 0.86)
0.11 (95% CI: –0.61, 0.82)
0.13 (95% CI: –0.59, 0.85)
Overall safety analysis set
Patients with past history of hypertension
Patients hypertensive at screening
Patients with no hypertension at screening
β-blocker users
Non β-blocker users
With age group (<45, ≥45 to <65, ≥65 years)
With antihypertensive use at screening
Overall safety analysis set
Patients with past history of hypertension
Patients hypertensive at screening
Patients with no hypertension at screening
β-blocker users
Non β-blocker users
With age group (<45, ≥45 to <65, ≥65 years)
With antihypertensive use at screening
Adjusted change from baseline to EoT Adjusted change from baseline to  EoT
–10–5 –50 5 0 510
Pulse rate (bpm): combination vs solifenacin 5 mg
Adjusted change from baseline to EoT
0.04 (95% CI: –0.75, 0.82)
–0.64 (95% CI: –6.26, 4.98)
–0.07 (95% CI: –1.42, 1.28)
0.04 (95% CI: –0.93, 1.01)
–0.92 (95% CI: –3.13, 1.28)
0.2 (95% CI: –0.64,1.05)
0.07 (95% CI: –0.72, 0.85)
0.03 (95% CI: –0.75, 0.82)
Pulse rate (bpm): combination vs solifenacin 10 mg
Adjusted change from baseline to  EoT
Overall safety analysis set
Patients with past history of hypertension
Patients hypertensive at screening
Patients with no hypertension at screening
β-blocker users
Non β-blocker users
With age group (<45, ≥45 to <65, ≥65 years)
With antihypertensive use at screening
Overall safety analysis set
Patients with past history of hypertension
Patients hypertensive at screening
Patients with no hypertension at screening
β-blocker users
Non β-blocker users
With age group (<45, ≥45 to <65, ≥65 years)
With antihypertensive use at screening
0.19 (95% CI: –0.59, 0.99)
1.12 (95% CI: –4.62, 6.86)
0.07 (95% CI: –1.29, 1.43)
0.21 (95% CI: –0.76, 1.18)
–0.26 (95% CI: –2.42, 1.90)
0.24 (95% CI: –0.60, 1.09)
0.21 (95% CI: –0.58, 0.99)
0.19 (95% CI: –0.59, 0.98)
–5–5–10 00 5 0 5 10
(A)
(B)
(C)
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tachycardia	(reported	as	a	TEAE	by	the	investigator	or	a	mean	pulse	
rate	≥100	bpm)	with	combination	therapy	(1.4%)	was	lower	than	that	
reported with mirabegron 50 mg monotherapy in the previous 12- 
week	studies	(3.8%).29
The	frequency	of	CV	TEAEs	reported	in	BESIDE	compares	favour-
ably	with	 the	 rate	of	CV	events	 reported	 in	 the	general	population.	
In the Framingham study, after 30 years of follow- up, the frequency 
of	 hypertension	 (SBP	≥160	mm	Hg	 and	DBP	≥95	mm	Hg)	 increased	
with	age	in	men	from	3.3%	at	ages	30-	39	to	6.2%	at	ages	70-	79,	and	
in	women	from	1.5%	at	ages	30-	39	to	8.6%	at	ages	70-	79.30	The	fre-
quency	of	tachycardia	(≥100	bpm)	in	the	general	US	population	based	
on	national	 reference	data	on	resting	pulse	rate	 is	1.3%	 in	men	and	
1.9%	in	women.31
The	only	notable	difference	in	vital	signs	between	combination	
and	solifenacin	monotherapy	in	BESIDE	was	the	1	mm	Hg	relative	
difference	 in	 SBP,	which	was	 unchanged	with	 combination	 ther-
apy	 and	 decreased	with	 solifenacin	 monotherapy.	 The	 negligible	
effects on vital signs are reflected by the fact that only eight pa-
tients	 (combination	 n=1,	 solifenacin	 5	mg	n=2,	 solifenacin	 10	mg	
n=5)	had	potentially	significant	increases	in	blood	pressure	during	
the study.
The	 frequency	 of	 ECG	 QT	 prolongation	 was	 0.1%	 in	 each	
treatment	group	and	there	were	no	cases	of	extreme	QTcF	values	
>500 mseconds. Five solifenacin- treated patients experienced a 
change	in	QTcF	>60	mseconds	during	the	study	compared	with	none	
in the combination group. Regardless of treatment, female patients 
were	more	 likely	 to	 experience	 extreme	QTcF	 values	 >450	msec-
onds and >480 mseconds than males, which reflects the observa-
tion	that	corrected	QT	intervals	are	generally	longer	in	women	than	
in men.32
TABLE  3 Adjusted	change	from	baseline	to	EoT	in	vital	signs	by	sex
Mean (SE) [95% CI]
Combination Solifenacin 5 mg Solifenacin 10 mg
Males n=119 n=120 n=114
Systolic	blood	pressure
Adjusted	change	from	baseline 1.82	(0.94)	[−0.03	to	3.67] 1.46	(0.93)	[−0.37	to	3.29] 0.89	(0.96)	[−0.99	to	2.78]
Difference vs. solifenacin 5 mg 0.36	(1.32)	[−2.23	to	2.95]
Difference vs. solifenacin 10 mg 0.92	(1.34)	[−1.70	to	3.55]
Diastolic blood pressure
Adjusted	change	from	baseline 1.37	(0.63)	[0.14	to	2.61] 1.10	(0.63)	[−0.13	to	2.34] 0.43	(0.64)	[−0.83	to	1.70]
Difference vs. solifenacin 5 mg 0.27	(0.89)	[−1.47	to	2.01]
Difference vs. solifenacin 10 mg 0.94	(0.90)	[−0.82	to	2.71]
Pulse	rate
Adjusted	change	from	baseline 0.28	(0.69)	[−1.07	to	1.64] 1.41	(0.69)	[0.06	to	2.76] 0.26	(0.71)	[−1.13	to	1.65]
Difference vs. solifenacin 5 mg −1.13	(0.97)	[−3.04	to	0.79]
Difference vs. solifenacin 10 mg 0.02	(0.99)	[−1.91	to	1.96]
Females n=587 n=591 n=592
Systolic	blood	pressure
Adjusted	change	from	baseline −0.27	(0.42)	[−1.10	to	0.55] −1.41	(0.42)	[−2.24	to	−0.59] −1.71	(0.42)	[−2.53	to	−0.89]
Difference vs. solifenacin 5 mg 1.14	(0.59)	[−0.03	to	2.31]
Difference vs. solifenacin 10 mg 1.44	(0.59)	[0.27	to	2.60]
Diastolic blood pressure
Adjusted	change	from	baseline −0.69	(0.28)	[−1.25	to	−0.14] −0.76	(0.28)	[−1.32	to	−0.21] −0.66	(0.28)	[−1.22	to	−0.11]
Difference vs. solifenacin 5 mg 0.07	(0.40)	[−0.71	to	0.85]
Difference vs. solifenacin 10 mg −0.03	(0.40)	[−0.81	to	0.75]
Pulse	rate
Adjusted	change	from	baseline 0.50	(0.31)	[−0.11	to	1.11] 0.23	(0.31)	[−0.38	to	0.84] 0.27	(0.31)	[−0.33	to	0.88]
Difference vs. solifenacin 5 mg 0.27	(0.44)	[−0.59	to	1.13]
Difference vs. solifenacin 10 mg 0.23	(0.44)	[−0.63	to	1.09]
Adjusted	change	from	baseline	values	and	95%	CIs	are	generated	from	ANCOVA	model	with	treatment	group,	gender,	age	group,	4-	week	incontinence	
reduction	group,	geographic	region	and	interaction	between	age	group	(<65,	≥65	years)	and	treatment	group	as	fixed	factors	and	baseline	as	a	covariate.
Differences of adjusted means are calculated by subtracting adjusted mean of solifenacin treatment from adjusted mean of combination treatment.
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A	 substantial	 proportion	 of	 the	 BESIDE	 population	was	 taking	
medication to control hypertension, which may have concealed po-
tential increases in blood pressure; however, this would apply across 
all treatment arms. Furthermore, the study lacked a placebo arm, 
which	would	have	allowed	a	more	robust	comparison	of	CV	safety	
between active treatment and a control cohort in this refractory in-
continent	population.	 In	 this	paper,	CV	safety	was	not	 reported	 in	
patients	 stratified	by	older	age	 (≥65	years	and	≥75	years)—the	co-
hort	most	likely	to	have	pre-	existing	CV	morbidities	and	at	risk	of	de-
veloping	CV-	related	AEs—results	for	these	patients	will	be	presented	
in	a	subsequent	analysis	in	older	patients	from	the	BESIDE	study.
In	addition	to	the	safety	analysis	in	older	patients	in	BESIDE,	fu-
ture subanalyses using integrated clinical trial data could investigate 
combination	therapy	vs.	placebo	in	other	high	risk	CV	populations	(eg,	
diabetes,	hypertension,	and	BMI	>30),	and	compare	office-	based	vs.	
ambulatory blood pressure monitoring.
5  | CONCLUSION
In	OAB	patients	treated	with	a	combination	of	mirabegron	and	solif-
enacin,	the	frequency	of	CV-	related	AEs	and	changes	from	baseline	
in	vital	signs	and	ECG	parameters	were	comparable	with	the	recom-
mended	 doses	 of	 solifenacin	 monotherapy	 (5	mg	 and	 10	mg),	 indi-
cating	a	 lack	of	a	synergistic	effect	on	CV	safety	with	combination.	
However, good clinical practice advocates regular blood pressure 
monitoring	 in	 older	 patients	where	 CV	 risk	may	 be	 cumulative	 be-
cause of comorbidities or co- medication.
F IGURE  2 A-	C,	Patients	meeting	change	from	baseline	criteria	for	systolic	blood	pressure	(A),	diastolic	blood	pressure	(B)	and	pulse	
rate	(C)
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TABLE  4 Patients	meeting	change	from	baseline	criteria	in	vital	signs	by	subpopulation	(based	on	patients	with	three	consecutive	
postbaseline	values):	past	history	of	hypertension;	hypertensive	at	screening;	no	hypertension	at	screening;	β- blocker user; non β- blocker user
Combination Solifenacin 5 mg Solifenacin 10 mg
Past	history	of	hypertension n=17 n=18 n=17
SBP:	increase	from	baseline
≥10	mm	Hg 0 2	(11.1%) 0
≥15	mm	Hg 0 0 0
≥20	mm	Hg 0 0 0
DBP:	increase	from	baseline
≥5	mm	Hg 0 0 2	(11.8%)
≥10	mm	Hg 0 0 1	(5.9%)
≥15	mm	Hg 0 0 0
Pulse	rate:	increase	from	baseline
≥5	bpm 3	(17.6%) 0 0
≥10	bpm 2	(11.8%) 0 0
≥15	bpm 1	(5.9%) 0 0
Hypertensive at screening n=255 n=254 n=248
SBP:	increase	from	baseline
≥10	mm	Hg 11	(4.3%) 10	(3.9%) 10	(4.0%)
≥15	mm	Hg 4	(1.6%) 4	(1.6%) 6	(2.4%)
≥20	mm	Hg 2	(0.8%) 1	(0.4%) 3	(1.2%)
DBP:	increase	from	baseline
≥5	mm	Hg 22	(8.6%) 23	(9.1%) 21	(8.5%)
≥10	mm	Hg 6	(2.4%) 8	(3.1%) 5	(2.0%)
≥15	mm	Hg 0 2	(0.8%) 1	(0.4%)
Pulse	rate:	increase	from	baseline
≥5	bpm 15	(5.9%) 23	(9.1%) 16	(6.5%)	[n=247]
≥10	bpm 4	(1.6%) 10	(3.9%) 3	(1.2%)	[n=247]
≥15	bpm 1	(0.4%) 1	(0.4%) 0
No hypertension at screening n=455 n=461 n=461
SBP:	increase	from	baseline
≥10	mm	Hg 13	(2.9%) 21	(4.6%) 16	(3.5%)
≥15	mm	Hg 9	(2.0%) 9	(2.0%) 3	(0.7%)
≥20	mm	Hg 0 3	(0.7%) 2	(0.4%)
DBP:	increase	from	baseline
≥5	mm	Hg 31	(6.8%) 33	(7.2%) 36	(7.8%)
≥10	mm	Hg 9	(2.0%) 10	(2.2%) 9	(2.0%)
≥15	mm	Hg 1	(0.2%) 2	(0.4%) 3	(0.7%)
Pulse	rate:	increase	from	baseline
≥5	bpm 32	(7.0%) 30	(6.5%) 43	(9.3%)
≥10	bpm 10	(2.2%) 6	(1.3%) 9	(0.2%)
≥15	bpm 4	(0.9%) 1	(0.2%) 1	(0.2%)
β- blocker users n=85 n=92 n=101
SBP:	increase	from	baseline
≥10	mm	Hg 2	(2.4%) 2	(2.2%) 4	(4.0%)
≥15	mm	Hg 1	(1.2%) 2	(2.2%) 1	(1.0%)
≥20	mm	Hg 0 0 0
(Continues)
12 of 15  |     DRAKE Et Al.
F IGURE  3 Vital	sign	shift	at	EoT
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Combination Solifenacin 5 mg Solifenacin 10 mg
DBP:	increase	from	baseline
≥5	mm	Hg 6	(7.1%) 4	(4.3%) 4	(4.0%)
≥10	mm	Hg 2	(2.4%) 1	(1.1%) 1	(1.0%)
≥15	mm	Hg 0 0 0
Pulse	rate:	increase	from	baseline
≥5	bpm 4	(4.7%) 6	(6.5%) 10	(9.9%)
≥10	bpm 0 3	(3.3%) 2	(2.0%)
≥15	bpm 0 1	(1.1%) 0
Non β- blocker users N=622 N=622 N=608
SBP:	increase	from	baseline
≥10	mm	Hg 22	(3.5%) 29	(4.7%) 22	(3.6%)
≥15	mm	Hg 12	(1.9%) 11	(1.8%) 8	(1.3%)
≥20	mm	Hg 2	(0.3%) 4	(0.6%) 5	(0.8%)
DBP:	increase	from	baseline
≥5	mm	Hg 46	(7.4%) 52	(8.4%) 53	(8.7%)
≥10	mm	Hg 13	(2.1%) 17	(2.7%) 13	(2.1%)
≥15	mm	Hg 1	(0.2%) 4	(0.6%) 4	(0.7%)
Pulse	rate:	increase	from	baseline
≥5	bpm 43	(6.9%) 47	(7.6%) 49	(8.1%)	[n=607]
≥10	bpm 14	(2.3%) 13	(2.1%) 10	(1.6%)	[n=607]
≥15	bpm 5	(0.8%) 1	(0.2%) 1	(0.2%)	[n=607]
DBP,	diastolic	blood	pressure;	SBP,	systolic	blood	pressure.
TABLE  4  (Continued)
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Mean (SD)
Combination  
(n=725)
Solifenacin 5 mg  
(n=728)
Solifenacin 10 mg 
(n=719)
PR	duration	(mseconds)
Baseline 165.62	(23.08)	
[n=713]
165.18	(24.02)	[n=722] 165.15	(22.89)	[n=714]
EoT 165.52	(22.91)	
[n=703]
165.48	(23.57)	[n=710] 166.20	(22.49)	[n=704]
Change from 
baseline
0.08	(11.82)	[n=699] 0.48	(11.97)	[n=708] 0.95	(10.67)	[n=704]
RR	duration	(mseconds)
Baseline 894.20	(131.01)	
[n=721]
891.15	(136.96)	[n=727] 892.71	(123.71)	[n=719]
EoT 870.00	(123.13)	
[n=710]
877.50	(136.25)	[n=714] 880.70	(130.68)	[n=709]
Change from 
baseline
−23.07	(102.39)	
[n=707]
−13.34	(106.44)	[n=713] −12.29	(102.12)	[n=709]
QRS	duration	(mseconds)
Baseline 92.92	(9.58)	[n=721] 92.74	(10.10)	[n=727] 92.46	(8.60)	[n=719]
EoT 93.71	(9.88)	[n=710] 93.48	(9.81)	[n=714] 93.47	(8.82)	[n=709]
Change from 
baseline
0.82	(5.19)	[n=707] 0.73	(6.10)	[n=713] 0.98	(6.23)	[n=709]
QTcF	(mseconds)
Baseline 417.34	(18.00)	
[n=721]
416.52	(18.09)	[n=727] 415.42	(17.85)	[n=719]
EoT 417.85	(18.99)	
[n=710]
417.35	(17.67)	[n=714] 418.77	(19.01)	[n=709]
Change from 
baseline
0.49	(13.23)	[n=707] 0.77	(12.98)	[n=713] 3.30	(13.72)	[n=709]
Heart	rate	(bpm)
Baseline 68.61	(9.90)	[n=721] 69.03	(10.53)	[n=727] 68.63	(9.73)	[n=719]
EoT 70.41	(9.77)	[n=710] 70.13	(10.84)	[n=714] 69.73	(10.43)	[n=709]
Change from 
baseline
1.71	(8.19)	[n=707] 1.08	(8.65)	[n=713] 1.12	(8.22)	[n=709]
EoT,	end	of	treatment;	QTcF,	QT	interval	corrected	using	Fridericia’s	formula.
TABLE  5 12-lead	ECG	results:	mean	
values	and	change	from	baseline	at	EoT	
(assessment	by	central	reader)
F IGURE  4 Shift	categories	for	
interpretation of 12-lead electrocardiogram 
results during double- blind treatment 
(assessment	by	central	reader) Worst case assessment value reported among all measurements at any visit during the double-blind period for each subject was used for the summary
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